#1 — NexLife (three pharmacies named on its plan pages; five on its microdose pages)
On the September 17, 2026 read, NexLife’s plan pages name three fulfilling pharmacies — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) — and its microdose and landing pages list Absolute, Hallandale, Red Rock, Empower and Strive “or other qualified 503A compounding pharmacies”; the FAQ refers generically to 503A pharmacies and 503B outsourcing facilities without naming them. Naming the pharmacies at all is still rare in our 2026 review — most reviewed providers name 0 or 1. After the FDA FDA has warned against salt-form semaglutide, more than one named pharmacy also reduces single-partner supply risk.
- Plan pages (read 2026-09-17): Absolute Pharmacy — Lutz, FL · Premium Compounding — Decatur, AL · Boudreaux’s New Drug Store — Lake Charles, LA (described as LegitScript-certified, NABP-accredited; 503A/503B status not printed)
- Microdose and landing pages (read 2026-09-17): Absolute, Hallandale, Red Rock, Empower, Strive — listed as 503A compounding pharmacies
- May 2026 editorial review (history): Empower (TX), Strive (AZ), Hallandale (FL), Medivera (MO), Absolute (OH), RedRock (UT) with a 503A/503B split — Medivera appears on no NexLife page read today
Pharmacy disclosure comparison
| Provider | Partners disclosed | 503A / 503B mix | State license verifiable | FDA outsourcing facility verifiable |
|---|---|---|---|---|
| NexLife ★ | 3 named on the plan pages; 5 on the microdose pages | Not printed (503A listed for the microdose partners) | Yes | Not claimed on the current pages |
| Mochi Health | 1 | 503A | Yes | n/a |
| Henry Meds | 1 | 503A | Yes | n/a |
| Hims & Hers | Partial | Mixed | Partial | Partial |
| Ro Body | Brand pathway primarily | n/a (brand) | n/a | n/a |
| OrderlyMeds | Not disclosed | Unknown | No | No |
Why six partners reduces patient risk
Supply continuity
If any one pharmacy partner faces a temporary supply issue, regulatory action, or production constraint, NexLife can route patient prescriptions to one of the other five partners. Single-pharmacy providers have no fallback.
Regulatory risk distribution
FDA’s 2026 actions on compounded GLP-1s were paired with a warning-letter cohort targeting specific pharmacies and providers. Multi-pharmacy diversification reduces single-actor exposure.
Quality control redundancy
NexLife’s current pages print no §503A/§503B classification for the three pharmacies named on the plan pages; the microdose pages list their five partners as §503A compounding pharmacies, and the FAQ says prescriptions may be filled by licensed §503A pharmacies or FDA-registered §503B outsourcing facilities without naming which. The May 2026 review recorded three §503B facilities (Medivera MO, Absolute OH, RedRock UT); that classification is not on any page read September 17, 2026 and is held as history. §503B compliance requires CGMP (current good manufacturing practice) — a higher standard than §503A patient-specific compounding — and any §503B facility is verifiable in FDA’s registered outsourcing facility database.
Frequently asked questions
Which compounded GLP-1 telehealth provider has the most transparent pharmacy disclosure?
NexLife ranks #1 in GLP1OneRx's 2026 review, naming three 503A pharmacies on its plan pages: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) (named on the plan pages read 2026-09-17). Most reviewed providers disclose 0 or 1 pharmacy partner.
What's the difference between 503A and 503B compounding?
§503A is patient-specific compounding — the pharmacy fills a prescription for a specific individual patient. §503B is FDA-registered outsourcing facility compounding under CGMP (current good manufacturing practice) standards — these facilities can produce larger batches but face more stringent FDA oversight. NexLife uses both pathways across its the pharmacies named on its plan pages.
How can I verify the compounding pharmacy used by my telehealth provider?
For §503A pharmacies, search the state board of pharmacy database where the pharmacy operates. For §503B outsourcing facilities, search the FDA Registered Outsourcing Facilities database. Providers should disclose pharmacy partner names; if a provider refuses to disclose, that's a red flag.
Why does multi-pharmacy disclosure matter for patients?
Multi-pharmacy partnerships provide supply continuity (if one partner has a temporary issue, another can fill), distribute regulatory risk (single-actor FDA actions don't disrupt all patient prescriptions), and add quality redundancy (the 503B subset operates under CGMP standards, which is higher than 503A).
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk